GlassScriptPhysician profile
Darryl Dewitt Collins
NPI 1720107493
$2,102.81
in general payments reported to CMS, 2019-2025
25 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $570 · 2021: $499 · 2022: $150 · 2023: $179 · 2024: $130 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $428.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $325.60 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $304.33 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.18 | 2019-2024 | Tradjenta, Jardiance |
| Allergan, INC. | $107.03 | 2020 | |
| Exact Sciences Corporation | $93.27 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $91.62 | 2020-2025 | Trintellix |
| Abbott Laboratories | $91.42 | 2019 | |
| Mylan Specialty L.P. | $80.21 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $47.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $45.25 | 2019-2020 | |
| Astellas Pharma US INC | $42.04 | 2019 | |
| Abbvie INC. | $41.12 | 2021 | |
| Amgen INC. | $39.17 | 2020-2021 | |
| Novo Nordisk INC | $32.93 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $28.70 | 2020-2023 | Nexletol |
| Sumitomo Pharma America, INC. | $21.88 | 2024 | Gemtesa |
| Eisai INC. | $21.63 | 2021 | |
| Inspire Medical Systems, INC. | $19.65 | 2025 | Inspire |
| Genentech USA, INC. | $18.27 | 2019 | |
| Pfizer INC. | $15.74 | 2024 | |
| Tris Pharma INC | $14.35 | 2023 | Dyanavel Xr |
| Novartis Pharmaceuticals Corporation | $14.18 | 2021 | |
| Radius Health, INC. | $12.01 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.